Comparative Pharmacology
Head-to-head clinical analysis: EXONDYS 51 versus SPINRAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXONDYS 51 versus SPINRAZA.
EXONDYS 51 vs SPINRAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, inducing skipping of exon 51 during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) who have confirmed mutations amenable to exon 51 skipping.
SPINRAZA (nusinersen) is an antisense oligonucleotide that modifies splicing of pre-messenger RNA of the survival motor neuron 2 (SMN2) gene to increase production of full-length SMN protein, which is deficient in spinal muscular atrophy (SMA).
30 mg/kg intravenously over 35-60 minutes once weekly
Loading dose: 12 mg (5 mL) intrathecally on days 0, 14, 28, and 63. Maintenance dose: 12 mg (5 mL) intrathecally once every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 28-32 days. This long half-life supports weekly dosing intervals.
Terminal elimination half-life in cerebrospinal fluid (CSF) is 135–177 days; in plasma, it is 63–87 days. The long CSF half-life supports monthly intrathecal dosing.
Primarily eliminated via renal excretion as intact oligonucleotide. Approximately 30-40% of administered dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Primarily metabolized via exonuclease-mediated hydrolysis; renal excretion of intact drug is negligible (<1%). No biliary or fecal elimination is documented.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide